-
A new agent has been approved by the fda for the treatment of thrombocytopenia associated with chronic immune thrombocytopenia purpura (ITP).
-
Terminally ill cancer patients who had end-of life discussions with their physician had better quality of life during their last week and their caregivers had an easier bereavement.
-
-
Ongoing safety review of tiotropium; raloxifene reduces the risk of endometrial cancer; one-day treatment with famciclovir may be as effective as 3-day treatment with valacyclovir; new Clinical Practice Guideline from the American College of Physicians regarding pharmacologic treatment for low bone density and osteoporosis; FDA Actions.
-
-
-
Increased migraine attack frequency and overuse of acute medication, especially barbiturates and opiates, are risk factors for the chronification of migraine, which occurs in up to 2% of individuals.
-
The Babinski sign continues to be a valid bed-side test for pyramidal tract lesions.
-
A randomized, controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Perhaps the most prominent cardiovascular report in 2007 was the publication of the COURAGE trial (N Engl J Med. 2007;356:1503-1516), which demonstrated the equality in major CV outcomes in randomized patients with stable CAD, most with angina, who were assigned PCI with optimal medical therapy (OMT) vs OMT alone, with a mean follow-up of 4.6 years.